Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical United States Legal Issues

Government’s RICO Case Against NECC is Unprecedented

This article was originally published in The Gold Sheet

  • News

Executive Summary

A 131-count indictment unsealed last month that includes murder and racketeering allegations against New England Compounding Center pharmacists for violations of the FD&C Act is unprecedented and signals that the federal government is using more aggressive legal tools in prosecuting individuals whose products harm or kill consumers.

You may also be interested in...



A Lesson on Outsourcing: The NECC Fungal Meningitis Outbreak

Firms That Get Complete Response Letters Might Get Inspected By US FDA Six Months After Replies

While COVID-19 continues to wreak havoc on FDA's ability to perform onsite preapproval inspections, new guidance offers some clarity, but the news isn't great for ANDA holders.

COVID-19 Spurs WHO To Revise Guidance On Technology Transfers

The WHO proposes to revise 2011 guidance on technology transfers to ease the hand-off of COVID-19 drugs and vaccines from research and development facilities to commercial sites.

Table

View full table

Topics

Tags:
BioPharmaceutical United States Legal Issues
UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By